Determination of inosine monophosphate dehydrogenase activity in human CD4+ cells isolated from whole blood during mycophenolic acid therapy.
Inosine 5'-monophosphate dehydrogenase (IMPDH) is an established target in immunosuppression following organ transplantation. In lymphocytes, reversible inhibition of this enzyme by mycophenolic acid (MPA) results in reduced production of guanine and deoxyguanine nucleotides and thereby retarded proliferation of activated cells. In order to examine MPA pharmacodynamics in renal allograft recipients, the authors have developed an assay for the determination of IMPDH activity in CD4+ cells directly isolated from a small blood volume. Paramagnetic beads coated with anti-CD4 antibodies were utilized for the cell isolation. The intracellular MPA concentration was restored by incubating the cells in microfiltrated plasma from the original sample. Inosine 5'-monophosphate (IMP; substrate) and nicotine adenine dinucleotide (NAD; co-factor) were added to cell lysates, and IMPDH activity was quantified as the xanthosine 5'-monophosphate (XMP) production rate (pmol/10 cells/min) determined by liquid chromatography after hydrolytic cleavage to xanthine. The reaction kinetics were saturated with IMP and NAD concentrations of 1.79 micromol/L and 0.38 micromol/L, respectively. The production rate was linear in the interval 0.13 to 8.7 pmol XMP/min. Total interseries CVs based on seven replicates at each MPA concentration 0, 2.2, and 8.6 microg/mL were 25%, 16%, and 13%, respectively. When a single 1 gram mycophenolate mofetil dose was administered to a healthy individual, the measured IMPDH activity was 13% of predose value at the MPA peak concentration. The present assay allows reliable determination of IMPDH activity in CD4+ cells during MPA exposure, reducing the potential influence of sample preparation on the measured enzyme activity to a minimum. The assay may be applied to assess MPA pharmacodynamics during immunosuppressive treatment, maintaining the influence of intracellular MPA on the IMPDH activity.
Vethe
Nils Tore
NT
Department of Medical Biochemistry, Rikshospitalet University Hospital, Oslo, Norway.
Bergan
Stein
S
D015704:CD4 Antigens / Q000187:drug effects / Q000302:isolation & purification / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D007168:IMP Dehydrogenase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D007166:Immunosuppressive Agents / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009173:Mycophenolic Acid / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use
D015704:CD4 Antigens; D007166:Immunosuppressive Agents; D007168:IMP Dehydrogenase; D009173:Mycophenolic Acid